CME Group Board Member Increases Stake to 4,200 Shares Through Director Compensation

Rhea-AI Filing Summary

CME Group director Daniel G. Kaye reported an acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted pursuant to the CME Group Director Stock Plan.

Following this transaction, Kaye now beneficially owns 4,200 shares directly. The filing indicates this was a planned acquisition under the company's director compensation program rather than an open market purchase.

• Transaction Type: Stock Grant (Code A)
• Reporting Person Role: Director
• Ownership Form: Direct
• Filing was submitted by Jenelle Chalmers on behalf of Daniel G. Kaye

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Kaye Daniel G

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock Class A	532	$273.03	$145K

Holdings After Transaction: Common Stock Class A — 4,200 shares (Direct)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kaye Daniel G

(Last) (First) (Middle)

20 S. WACKER DR.

(Street)

CHICAGO IL 60606

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CME GROUP INC. [ CME ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock Class A	06/25/2025		A(1)		532	A	$273.03	4,200	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Granted pursuant to the CME Group Director Stock Plan, as amended and restated.

Remarks:

	By: Jenelle Chalmers For: Daniel G. Kaye	06/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many CME Group shares did Director Daniel Kaye acquire on June 25, 2025?

Director Daniel G. Kaye acquired 532 shares of CME Group Class A Common Stock on June 25, 2025 at a price of $273.03 per share.

What is the total number of CME shares owned by Director Kaye after the June 2025 transaction?

Following the reported transaction, Director Daniel G. Kaye beneficially owned 4,200 shares of CME Group Class A Common Stock directly.

Under what plan were the CME shares granted to Director Kaye?

The shares were granted pursuant to the CME Group Director Stock Plan, as amended and restated.

Who filed the Form 4 for CME Director Daniel Kaye?

The Form 4 was filed by Jenelle Chalmers on behalf of Daniel G. Kaye on June 26, 2025.

What is Daniel Kaye's role at CME Group according to the Form 4?

According to the Form 4, Daniel G. Kaye serves as a Director of CME Group Inc., as indicated by the 'X' marked in the Director box under the Relationship of Reporting Person(s) to Issuer section.